Skip to main content
AngioLab, Inc. logo

AngioLab, Inc. — Investor Relations & Filings

Ticker · 251280 ISIN · KR7251280004 KO Professional, scientific and technical activities
Open in API
Filings indexed 174 across all filing types
Latest filing 2019-06-28 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 251280

About AngioLab, Inc.

https://angiolab.co.kr/

AngioLab, Inc. is a biotechnology company specializing in the discovery and development of angiogenesis inhibitors. The company develops pharmaceuticals and health functional foods to treat diseases associated with the abnormal growth of blood vessels. Its pipeline includes drug candidates targeting conditions such as age-related macular degeneration (AMD), with some candidates having undergone Phase II clinical trials. AngioLab has also developed Ob-X, a functional food ingredient based on its anti-angiogenic research platform.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). It outlines the issuance of new shares (third-party allocation), the purpose of the funds, the pricing methodology, and the specific details of the convertible redeemable preferred shares being issued. This falls under the category of announcements regarding new share issues and capital structure changes.
2019-06-28 Korean
기업설명회(IR)개최결과
Investor Presentation Classification · 95% confidence The document is a short, structured announcement detailing the results of an Investor Relations (IR) meeting held by AngioLab on May 23, 2019. It lists the time, location, attendees, and agenda items of the meeting. Since it is a brief regulatory disclosure regarding the occurrence and outcome of an event rather than the full presentation deck itself, it falls under the category of general regulatory announcements.
2019-05-23 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 95% confidence The document is a formal notification of the results of an Investor Relations (IR) meeting held by AngioLab. It provides details such as the date, location, attendees, and a summary of the topics discussed (company status, business operations, and Q&A). Since it is a short regulatory disclosure announcing the outcome of an event rather than the full presentation slides or a comprehensive financial report, it falls under the category of general regulatory announcements.
2019-05-21 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal notice announcing an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves or a financial report, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2019-05-14 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose of the meeting. It does not contain the actual presentation materials or financial results, but rather serves as a notification of the event. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Regulatory Filing (RNS) when it does not fit into more specific categories like RPA (which is usually for report publication). Given the nature of the announcement, RNS is the most appropriate fallback category.
2019-05-13 Korean
사업보고서 (2018.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'AngeoLab' (주식회사 안지오랩) for the fiscal year 2018. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a comprehensive financial document, not an announcement or a summary, and fits the definition of an Audit Report (AR). FY 2018
2019-04-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.